Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Prescribing Decisions May Depend Upon Disease State

Oct 25 2016

• By Sue Sutter

Related Content

UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense

Sep 22 2016

Biosimilar Guidance Development Timelines Criticized By Docs And Patients

Oct 21 2016

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Jul 15 2016

Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017

Aug 03 2016

How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?

Oct 19 2016

Related Companies

Express Scripts Holding Company

Novartis AG

Amgen, Inc.

Celltrion, Inc.

Pfizer Inc.

CVS Health Corp.

Additional Topics

United States Policy Biosimilars Reimbursement BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window